Comparing Jakafi vs Ruxolitinib
| Jakafi Remove Jakafi from your drug comparison | Ruxolitinib Remove Ruxolitinib from your drug comparison |
|---|
| Jakafi ruxolitinib Remove Jakafi from your drug comparison | Ruxolitinib Remove Ruxolitinib from your drug comparison | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescribed for Myelofibrosis, Graft-versus-host disease, Polycythemia Vera, Myeloproliferative Disorders. Jakafi may also be used for purposes not listed in this medication guide. |
Prescribed for Myelofibrosis, Graft-versus-host disease, Polycythemia Vera, Myeloproliferative Disorders. ruxolitinib may also be used for purposes not listed in this medication guide. |
||||||||
|
Prescription only |
Prescription only |
||||||||
Ratings & Reviews |
|||||||||
Drug Class |
|||||||||
Side Effects |
|||||||||
|
Common side effects include: anemia, balance impairment, dizziness, headache, labyrinthitis, meniere's disease, neutropenia, thrombocytopenia, vertigo, and orthostatic dizziness. See the full Jakafi side effects document. |
Commonly reported side effects include: anemia, balance impairment, dizziness, headache, labyrinthitis, meniere's disease, neutropenia, thrombocytopenia, vertigo, and orthostatic dizziness. See the full ruxolitinib side effects document. |
||||||||
Pricing and Coupons* Prices are without insurance |
|||||||||
View all Jakafi prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
Generic Availability |
|||||||||
|
No |
No |
||||||||
Dosage Form(s) Available |
|||||||||
|
N/A | ||||||||
Brand Names |
|||||||||
|
N/A |
Jakafi | ||||||||
Half LifeThe half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. |
|||||||||
|
5.8 hours |
5.8 hours |
||||||||
CSA Schedule**View glossary of terms. |
|||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
Pregnancy Category |
|||||||||
|
Category C
Risk cannot be ruled out
See the full Pregnancy Warnings document. |
Category C
Risk cannot be ruled out
See the full Pregnancy Warnings document. |
||||||||
Drug Interactions |
|||||||||
|
A total of 381 drugs are known to interact with Jakafi:
|
A total of 381 drugs are known to interact with ruxolitinib:
|
||||||||
Alcohol/Food/Lifestyle Interactions |
|||||||||
|
|
||||||||
Disease Interactions |
|||||||||
First Approval Date |
|||||||||
|
November 16, 2011 |
November 16, 2011 |
||||||||
WADA ClassView World Anti-Doping Agency classifications. |
|||||||||
|
N/A |
N/A |
||||||||
More Information |
|||||||||
Consumer Resources |
|||||||||
Professional Resources |
|||||||||
Related Treatment Guide |
|||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.